SCHEMBL5135348

SCHEMBL5135348

CCCCn1c(CN(Cc2ccccc2)Cc2cccc(I)c2)cnc1-c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.42
C5AR1 P21730 1/20 0.38
HSD11B1 P28845 2/20 0.37
BCHE P06276 2/20 0.36
PDE4B Q07343 2/20 0.34
NR1H3 Q13133 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
KDM4E B2RXH2 2/20 0.33
HSD17B10 Q99714 2/20 0.33
ADORA2B P29275 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
TP53 P04637 1/20 0.33
LMNA P02545 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136484 0.90 TSHR (0.45) TSHRC5AR1HSD11B1BCHEPDE4B
SCHEMBL5072278 0.90 TSHR (0.51) TSHRC5AR1HSD11B1BCHEPDE4B
SCHEMBL5137098 0.89 TSHR (0.44) TSHRC5AR1HSD11B1PDE4BNR1H3
SCHEMBL5136811 0.88 C5AR1 (0.55) TSHRC5AR1ALDH1A1LMNASMN1; SMN2
SCHEMBL5136052 0.86 TSHR (0.43) TSHRC5AR1HSD11B1BCHEPDE4B
SCHEMBL5136036 0.86 TSHR (0.45) TSHRC5AR1HSD11B1PDE4BNR1H3
SCHEMBL5137319 0.86 TSHR (0.47) TSHRC5AR1HSD11B1BCHEPDE4B
SCHEMBL5070162 0.86 TSHR (0.47) TSHRC5AR1HSD11B1PDE4BNR1H3
SCHEMBL5135378 0.86 CALM1 (0.45) TSHRBCHENR1H3ALDH1A1MAPK1
SCHEMBL5137333 0.86 BCHE (0.44) TSHRC5AR1HSD11B1BCHEHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed